Atazanavir and lopinavir profile in pregnant women with HIV: Tolerability, activity and pregnancy outcomes in an observational national study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1377-1384

  Floridia, Marco ^a   Ravizza, Marina ^b   Masuelli, Giulia ^c   Giacomet, Vania ^d   Martinelli, Pasquale ^e   Antoni, Anna Degli ^f   Spinillo, Arsenio ^g   Fiscon, Marta ^h   Francisci, Daniela ⁱ   Liuzzi, Giuseppina ^j   Pinnetti, Carmela ^j   Marconi, Anna Maria ^b   Tamburrini, Enrica ^k   Mori, F ^l   Ortolani, P ^l   Dalle Nogare, E R ^l   Di Lorenzo, F ^l   Sterrantino, G ^l   Meli, M ^l   Polemi, S ^l   Nocentini, J ^l   Baldini, M ^l   Montorzi, G ^l   Mazzetti, M ^l   Rogasi, P ^l   Borchi, B ^l   Vichi, F ^l   Del Pin, B ^l   Pinter, E ^l   Anzalone, E ^l   Marocco, R ^l   Mastroianni, C ^l   Mercurio, V S ^l   Carocci, A ^l   Grilli, E ^l   Maccabruni, A ^l   Zaramella, M ^l   Mariani, B ^l   Natalini Raponi, G ^l   Guaraldi, G ^l   Nardini, G ^l   Stentarelli, C ^l   Beghetto, B ^l   Molinari, A ^l   Crisalli, M P ^l   Donisi, A ^l   Piepoli, M ^l   Cerri, V ^l   Zuccotti, G ^l   Fabiano, V ^l   Placido, G ^l   Vivarelli, A ^l   Castelli, P ^l   Savalli, F ^l   Portelli, V ^l   Sabbatini, F ^l   Bernini, L ^l   Grossi, P ^l   Rizzi, L ^l   Alberico, S ^l   Maso, G ^l   Airoud, M ^l   Soppelsa, G ^l   Meloni, A ^l   Dedoni, M ^l   Cuboni, C ^l   Ortu, F ^l   Piano, P ^l   Citernesi, A ^l   Bordoni Vicini, I ^l   Luzi, K ^l   Roccio, M ^l   Vimercati, A ^l   Miccolis, A ^l   Bassi, E ^l   Guerra, B ^l   Cervi, F ^l   Puccetti, C ^l   Murano, P ^l   Contoli, M ^l   Capretti, M G ^l   Marsico, C ^l   Faldella, G ^l   Sansone, M ^l   Agangi, A ^l   Tibaldi, C ^l   Trentini, L ^l   Todros, T ^l   Frisina, V ^l   Cetin, I ^l   Brambilla, T ^l   Savasi, V ^l   Personeni, C ^l   Giaquinto, C ^l   Rinaldi, R ^l   Rubino, E ^l   Bucceri, A ^l   Matrone, R ^l   Scaravelli, G ^l   Fundaro C ^l   Genovese, O ^l   Cafforio, C ^l   Tozzi, V ^l   Massetti, P ^l   Casadei, A M ^l   Cavaliere, A F ^l   Finelli, V ^l   Cellini, M ^l   Castelli Gattinara, G ^l   Dalzero, S ^l   Sacchi, V ^l   De Pirro, A ^l   Polizzi, C ^l   Mattei, A ^l   Pirillo, M F ^l   Amici, R ^l   Galluzzo, C M ^l   Donnini, S ^l   Baroncelli, S ^l   Regazzi, M ^l   Villani, P ^l   Cusato, M ^l   Cerioli, A ^l   De Martino, M ^l   Mastroiacovo, P ^l   Moroni, M ^l   Parazzini, F ^l   Vella, S ^l   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l NONE

more..

Author keywords

Bilirubin; Cholesterol; HIV RNA; Pre term delivery; Triglycerides

Indexed keywords

ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; CHOLESTEROL; GLUCOSE; LOPINAVIR; TRIACYLGLYCEROL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPID; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONCEPTION; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MATERNAL WELFARE; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; THIRD TRIMESTER PREGNANCY; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; BLOOD; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; LIVER FUNCTION TESTS; LOPINAVIR; OLIGOPEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PYRIDINES; RNA, VIRAL; VIRAL LOAD;

EID: 84898467141     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt497     Document Type: Article

References (32)

1. CDC. Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. Morb Mortal Wkly Rep 2006; 55: 592-7.
2. Townsend CL, Cortina-Borja M, Peckham CS et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-81.
3. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010; issue 3: CD008440.
4. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2013. Wilmington, NC: Registry Coordinating Center, 2013. http://www.apregistry.com/forms/interim_report.pdf (12 July 2013, date last accessed).
5. Powis KM, Kitch D, Ogwu A et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204: 506-14.
6. Sibiude J, Warszawski J, Tubiana R et al. Premature delivery in HIVinfected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?. Clin Infect Dis 2012; 54: 1348-60.
7. Watts DH, Williams PL, Kacanek D et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013; 207: 612-21.
8. Panel on Treatment of HIV-Infected PregnantWomen and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 31 July 2012. http:// aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf (16 July 2013, date last accessed).
9. EACS. European AIDS Clinical Society Guidelines, Version 7.0, October 2013. http://www.eacsociety.org/Portals/0/Guidelines_Online_131014. pdf (16 December 2013, date last accessed).
10. Antinori A, Marcotullio S, Ammassari A et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol 2012; 35: 113-59.
11. Bertino E, Spada E, Occhi L et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 2010; 51: 353-61.
12. Floridia M, Mastroiacovo P, Tamburrini E et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; 120: 1466-76.
13. Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs 2013; 73: 229-47.
14. Simmons LE, Rubens CE, Darmstadt GL et al. Preventing preterm birth and neonatal mortality: exploring the epidemiology, causes, and interventions. Semin Perinatol 2010; 34: 408-15.
15. Garcia PM, Kalish LA, Pitt J et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341: 394-402.
16. Magder LS, Mofenson L, Paul ME et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005; 38: 87-95.
17. McDonald C, Uy J, HuWet al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26: 259-64.
18. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009; 69: 1107-40.
19. Eley T, Huang SP, Conradie F et al. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retrov 2013; 10: 1287-92.
20. Chmait R, Franklin P, Spector SA et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370-3.
21. Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002; 10: 187-91.
22. Tang JH, Sheffield JS, Grimes J et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107: 1115-9.
23. Tuomala RE,Watts DH, Li D et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449-73.
24. Watts DH, Balasubramanian R, Maupin RT Jr et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190: 506-16.
25. Hitti J, Andersen J, McComsey G et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196: 331-7.
26. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
27. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
28. Floridia M, Tamburrini E, Ravizza M et al. Lipid profile during pregnancy in HIV-infected women. HIV Clin Trials 2006; 7: 184-93.
29. Enquobahrie DA, Williams MA, Qiu C et al. Early pregnancy lipid concentrations and the risk of gestational diabetes mellitus. Diab Res Clin Pract 2005; 70: 134-42.
30. Clausen T, Djurovic S, Heriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG 2001; 108: 1081-7.
31. Di Cianni G, Miccoli R, Volpe L et al. Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. Diab Med 2005; 22: 21-5.
32. Mikolajczyk RT, Zhang J, Betran AP et al. A global reference for fetal-weight and birthweight percentiles. Lancet 2011; 377: 1855-61.